Ditropan Xl (oxybutynin chloride)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Oxybutynin, a synthetic tertiary amine, is a genitourinary antispasmodic agent.
USES: This is a long-acting form of oxybutynin that is used to treat overactive bladder and urinary conditions. It relaxes the muscles in the bladder to help decrease problems of urgency and frequent urination. Oxybutynin belongs to a class of drugs known as antispasmodics.
This medication is also used to treat children 6 years of age and older who have an overactive bladder due to certain nerve disorders (such as spina bifida).
Generic name: oxybutynin chloride
Pronunciation: (OX-i-BUE-ti-nin)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Ditropan Xl
Indications
The following indications are listed for Ditropan Xl:
- Bladder Hyperactivity
- Increased Urinary Frequency
- Neurogenic Bladder
- Urinary Urge Incontinence
- Urinary Urgency
Also known as: Detrusor Overactivity, Hypertonic Bladder, Hypertonicity Of Bladder, Low Compliance Of Bladder, Overactive Detrusor, Urge Incontinence, Urge Urinary Incontinence, Urinary Frequency.
Dosing
For the treatment of overactive bladder, the usual adult dosage of oxybutynin chloride (as conventional tablets or oral solution) is 5 mg 2 or 3 times daily with a maximum of 5 mg 4 times daily. A lower initial dosage (2.5 mg 2 or 3 times daily) is recommended for frail geriatric patients. The usual dosage in children older than 5 years of age is 5 mg twice daily with a maximum of 5 mg 3 times daily.
The usual initial adult dosage of oxybutynin chloride (as extended-release tablets (Ditropan(R) XL)) for the treatment of overactive bladder is 5 or 10 mg once daily, administered at approximately the same time each day. In pediatric patients 6 years of age and older, the usual initial dosage of extended-release oxybutynin chloride for the relief of symptoms of detrusor overactivity associated with a neurologic condition (e.g., spina bifida) is 5 mg once daily. Dosage of the drug should be adjusted according to the patient's response and tolerance. Generally, dosage is increased gradually at 7-day intervals in increments of 5 mg up to a maximum dosage of 30 mg daily (in adults) or 20 mg daily (in pediatric patients 6 years of age and older).
The usual initial adult dosage of oxybutynin (as the transdermal system (Oxytrol(R))) for the treatment of overactive bladder is 1 transdermal system (delivering 3.9 mg per day) applied twice weekly (every 3-4 days).
Oxybutynin chloride is administered orally, and oxybutynin is administered percutaneously by topical application of a transdermal system. Like other antimuscarinic agents, oxybutynin should probably be discontinued periodically to determine whether or not the patient can manage without the drug and to minimize any tendency for the patient to become resistant to the drug.
Oxybutynin chloride extended-release tablets should be swallowed intact with liquid, and should not be chewed, crushed, or broken. The extended-release preparation of the drug may be administered without regard to meals. Patients should be advised that the tablet shell does not dissolve and may be passed in the stool.
Patients receiving transdermal oxybutynin therapy should be carefully instructed in the use of the transdermal system. To obtain optimum results, patients also should be given a copy of the patient instructions provided by the manufacturer. Prior to application, the oxybutynin transdermal system should be removed from the protective pouch. The transdermal system should then be applied immediately to dry, intact skin on the abdomen, hip, or buttock. A new application site should be selected with each new system to avoid reapplication to the same site within 7 days. The used system should be discarded in a manner that prevents accidental application or ingestion by children, pets, or others.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
The manufacturer states that specific drug interaction studies with the oxybutynin transdermal system have not been conducted to date.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Reproduction studies in hamsters, mice, rabbits, and rats using oxybutynin have not revealed evidence of harm to the fetus. Safe use of oxybutynin during pregnancy has not been established, and the drug should be used in pregnant women or women who may become pregnant only when the potential benefits to the patient outweigh the possible risks to the fetus.
Since it is not known whether oxybutynin chloride is distributed into human milk, the drug should be used with caution in nursing women.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.